Reina Benabou Net Worth

Reina Benabou biography

Reina Benabou serves as Senior Vice President, Chief Development Officer of the Company. Prior to joining BTI, Dr. Benabou held numerous leadership roles at leading biopharma companies, including at Pfizer as Head of Global Medical Product Evaluation and in other principal medical affairs roles, at Novartis as VP & World Wide Medical Head for the Neuroscience Franchise, and most recently at Cognivue as Chief Medical Officer. She has built and led a variety of U.S. and global high performing development, medical, regulatory and safety teams responsible for the commercialization of multiple products, such as SUBOXONE ® for the treatment of opioid drug addiction, GEODON ® for the treatment of schizophrenia and manic symptoms of bipolar disorder, LYRICA ® for the treatment of neuropathic pain in diabetes, fibromyalgia and SCI and to control seizures, and GILENYA ® for the treatment of relapsing forms of multiple sclerosis. Dr. Benabou held academic appointments in the Neurology Departments of Mount Sinai School of Medicine and Columbia University in New York. She holds an M.D. from the Universidade de São Paulo and a Ph.D. in Neurological Sciences from the University of Montreal, Canada.

What's Reina Benabou's mailing address?

Reina's mailing address filed with the SEC is C/O BIOXCEL THERAPEUTICS, INC.,, 555 LONG WHARF DRIVE, NEW HAVEN, CT, 06511.

Insiders trading at BioXcel Therapeutics Inc

Over the last 7 years, insiders at BioXcel Therapeutics Inc have traded over $63,244,788 worth of BioXcel Therapeutics Inc stock and bought 45,656 units worth $321,105 . The most active insiders traders include Vimal Bio Xcel Holdings, In..., Vimal Mehta, and Krishnan Nandabalan. On average, BioXcel Therapeutics Inc executives and independent directors trade stock every 30 days with the average trade being worth of $29,814. The most recent stock trade was executed by Matthew T. Wiley on 15 June 2024, trading 750 units of BTAI stock currently worth $413.

What does BioXcel Therapeutics Inc do?

bioxcel therapeutics, inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. the company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. the company's two most advanced clinical development programs are bxcl501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and bxcl701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer.

BioXcel Therapeutics Inc executives and stock owners

BioXcel Therapeutics Inc executives and other stock owners filed with the SEC include:

• Vimal Mehta,
  President, Chief Executive Officer, Co-Founder, Secretary, Director
• Dr. Vimal D. Mehta Ph.D.,
  Founder, CEO, Pres, & Director
• Frank Yocca,
  Chief Scientific Officer
• Vincent O'Neill,
  Chief Medical Officer
• Richard Steinhart,
  Chief Financial Officer
• Peter Mueller,
  Independent Chairman of the Board
• Sandeep Laumas,
  Independent Director
• Dr. Krishnan Nandabalan,
  Chief Digital Officer ?& Director
• Michal Votruba,
  Independent Director
• John Graziano,
  IR Contact Officer
• Reina Benabou,
  Senior Vice President, Chief Development Officer
• Will Kane,
  Executive Vice President, Chief Commercial Officer
• Krishnan Nandabalan,
  Co-Founder, Director, Chief Digital Officer
• Matthew Wiley,
  Sr. VP & Chief Commercial Officer
• Dr. Iris Francesconi Ph.D.,
  Sr. VP of Marketing, Market Research & Commercial Assessments
• Dr. Frank D. Yocca Ph.D.,
  Sr. VP & Chief Scientific Officer
• Richard I. Steinhart MBA,
  Sr. VP & CFO
• Dr. Reina Benabou M.D., Ph.D.,
  Sr. VP & Chief Devel. Officer
• William P. Kane Jr.,
  Exec. VP & Chief Commercial Officer
• Dr. David C. Hanley,
  Head of Global Pharmaceutical Devel. and Operations & VP
• Dr. Cedric Burg,
  VP and Head of Global Clinical Operations & Project Management
• Javier Rodriguez,
  Sr. VP, Chief Legal Officer & Corp. Sec.
• Mary Coleman,
  VP of Investment Relations
• Dr. Vincent J. O'Neill M.D., B.Sc., M.R.C.P.,
  Sr. VP & Chief Medical Officer
• Llc Bio Xcel,
  10% owner
• Holdings, Inc. Bio Xcel,
  10% owner
• Matthew T. Wiley,
  Chief Commercial Officer
• Michael Patrick Miller,
  Director
• June Bray,
  Director
• Vimal Bio Xcel Holdings, In...,
  CEO and President